We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Bristol Myers Squibb (BMY) Com Stk USD 0.10 (CDI)

Sell:$76.87 Buy:$76.88 Change: $0.16 (0.21%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Ex-dividend
Sell:$76.87
Buy:$76.88
Change: $0.16 (0.21%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Ex-dividend
Sell:$76.87
Buy:$76.88
Change: $0.16 (0.21%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Ex-dividend
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. The Company’s pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company’s products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.

Contact details

Address:
430 E 29th St Fl 14, 345 PARK AVE
NEW YORK
10154
United States
Telephone:
+1 (212) 5464000
Website:
https://www.bms.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BMY
ISIN:
US1101221083
Market cap:
$166.66 billion
Shares in issue:
2.13 billion
Sector:
Pharmaceuticals
Exchange:
New York Stock Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Giovanni Caforio
    Chairman of the Board, Chief Executive Officer
  • David Elkins
    Executive Vice President, Chief Financial Officer, Member of the Leadership Team
  • Ann Powell
    Chief Human Resource Officer, Senior Vice President, Member of the Leadership Team
  • Greg Meyers
    Executive Vice President, Chief Digital and Technology Officer, Member of the Leadership Team
  • Paul von Autenried
    Executive Vice President, Chief Information Officer, Member of the Leadership Team
  • Sandra Leung
    Executive Vice President, General Counsel, Member of the Leadership Team
  • Christopher Boerner
    Executive Vice President, Chief Commercial Officer, Member of the Leadership Team
  • Samit Hirawat
    Executive Vice President, Chief Medical Officer, Global Drug Development, Member of the Leadership Team
  • Elizabeth Mily
    Executive Vice President - Strategy and Business Development, Member of the Leadership Team
  • Louis Schmukler
    Executive Vice President, President - Global Product Development and Supply, Member of the Leadership Team

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.